Already have an account?

Login with an existing Projects In Knowledge account
New to Projects In Knowledge?

Register today to customize your experience.
Log In
Don't have an account yet? Click here to register

Register for Free
Already have an account? Click here to log in

Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.

Forgot Password

Please Enter your email address.

  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact

Revision date: This policy was last updated on September 30, 2003.

Education Initiative in Hematology

  • Multiple Myeloma — Multiple Myeloma: Second-Line Therapies Continue to Evolve – BreakingMED
  • While there is universal recognition of the need for second-line therapeutic regimens for multiple myeloma, determining the “best” choices as treatment moves from monotherapy to doublets and triplets is not straightforward.
    V. Abramson, MD
  • Multiple Myeloma — STOMP Trial Supports Selinexor in Myeloma Refractory to Anti-CD38 Monoclonal Antibodies – BreakingMED
  • Treatment combinations that incorporated selinexor—either selinexor plus pomalidomide or selinexor plus carfilzomib—improved progression-free survival and treatment response rates among patients with multiple myeloma who are refractory to anti-CD 38 monoclonal antibodies, researchers reported.
    V. Abramson, MD
  • Multiple Myeloma — Selinexor Add-on Active in Relapsed Multiple Myeloma – BreakingMED
  • A multi-drug combination including the exportin-1 inhibitor selinexor achieved an objective response among patients diagnosed with relapsed multiple myeloma after at least one line of treatment, researchers reported.
    V. Abramson, MD
  • Leukemia — Investigational BTK Inhibitor Pirtobrutinib Shows Promise for CLL – BreakingMED
  • A novel Bruton’s tyrosine kinase (BTK) inhibitor called pirtobrutinib showed substantial activity among patients diagnosed with chronic lymphocytic leukemia (CLL), with more than 90% of patients gaining clinical benefit from the treatment in early studies, researchers reported.
    V. Abramson, MD
  • Leukemia — CLL: Undetectable Disease Likely with Ibrutinib Plus Venetoclax – BreakingMED
  • Twenty months after stopping therapy, patients diagnosed with chronic lymphocytic leukemia (CLL) who were treated with the combination of ibrutinib plus venetoclax showed a marked difference in the rate of undetectable minimal residual disease when compared with patients treated with chlorambucil plus ... more >>
    V. Abramson, MD
  • Leukemia — CLL: Bruton’s TKIs Succeed Against TP53 Alterations – BreakingMED
  • Patients diagnosed with chronic lymphocytic leukemia (CLL) appear to do well when treated with inhibitors of Bruton’s tyrosine kinase across various TP53 gene alterations, researchers reported. First-line treatment with Bruton’s tyrosine kinase inhibitors—in 90% of the cases using the popular agent ibrutinib— ... more >>
    V. Abramson, MD
  • Multiple Myeloma — Multiple Myeloma: Isatuximab as Add-On to RVd Induction Improves MRD Negativity – BreakingMED
  • Adding an anti-CD38 monoclonal antibody (isatuximab [Sarclisa]) to lenalidomide/bortezomib/dexamethasone induction therapy for newly-diagnosed multiple myeloma (NDDM) significantly improved minimal residual disease (MRD) negativity, according to results of the Phase III GMMG-HD7 trial.
    V. Abramson, MD
  • Multiple Myeloma — Isatuximab Boosts Response to Second Line Tx in Elderly MM Patients – BreakingMED
  • The depth of response to first-line therapy for patients newly diagnosed with multiple myeloma is crucial, as it is predictive of long-term outcome, yet many patients—especially elderly patients—will need to proceed to second-line therapy. Slavisa Ninkovic, MBBS of the University of Melbourne and St. ... more >>
    A. Brixey, MD
  • Leukemia — Treatment Holiday Possible in CLL – BreakingMED
  • Patients diagnosed with chronic lymphocytic leukemia (CLL) who achieved undetectable minimal residual disease with combination ibrutinib and venetoclax appeared to maintain remission at two-year follow-up, even after discontinuing maintenance treatment with ibrutinib, researchers reported.
    V. Abramson, MD
  • Leukemia — Study Suggests Drug Holiday for Relapsed CLL Patients Feasible – BreakingMED
  • Patients diagnosed with relapsed or treatment refractory chronic lymphocytic leukemia (CLL) who achieved confirmed undetectable minimal residual disease may avoid treatment with maintenance agents and still achieve disease-free status for at least a year, according to findings from the VISION HO141 trial.
    V. Abramson, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Chronic Lymphocytic Leukemia @Point of Care
  • Recently approved targeted therapies and emerging immunotherapies for chronic lymphocytic leukemia (CLL) are transforming patient outcomes and the standard of care. To achieve the best patient outcomes, clinicians need to implement individualized treatment plans based upon evaluation of patient ... more >>
    S. Gregory, MD
  • Multiple Myeloma @Point of Care
  • This point-of-care eHandbook delivers a thorough yet concise review of multiple myeloma (MM), its diagnosis and prognosis, and the latest evidence-based data on treatment strategies with insights from top clinical specialists on the novel and emerging therapies that are revolutionizing the management of MM. ... more >>
    S. Lonial, MD
  • Cancer Care Considerations — Clinical Conversations: Promises of Targeting B7-H3 in the Treatment of Advanced Cancers – Webcast
  • Immune checkpoint inhibitor therapies are an exciting treatment modality for patients with a variety of cancers, with many recent FDA approvals in various settings and tumor types. The B7-H3 pathway is a novel immune checkpoint that is emerging as a promising treatment target. In this program, Cesar A. Perez, ... more >>
  • Cancer Care Considerations — Clinical Conversations: Promises of Targeting B7-H3 in the Treatment of Advanced Cancers – Webcast
  • Immune checkpoint inhibitor therapies are an exciting treatment modality for patients with a variety of cancers, with many recent FDA approvals in various settings and tumor types. The B7-H3 pathway is a novel immune checkpoint that is emerging as a promising treatment target. In this program, Melissa Johnson ... more >>
  • Leukemia — Future Treatment Landscape in CML – Webcast
  • This activity provides clinical strategies for evaluating clinical data on emerging tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML). Michael J. Mauro, MD, discusses why there is a need for new therapies for CML especially for later-line treatment and the latest data on ... more >>
  • Leukemia — Current Management With TKIs – Webcast
  • This activity provides an overview of current treatment approaches with the use of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia. Michael Deininger, MD, PhD, discusses key efficacy and safety data for the currently available TKIs, strategies to select TKI therapy for individual patients, and ... more >>
  • Leukemia — Optimizing TKI Management of Relapsed/Refractory CML – Webcast
  • This activity provides clinical strategies for both evaluating the indications for switching tyrosine kinase inhibitors (TKIs) due to resistance and/or intolerance and appropriate management of TKI-associated side effects. Nikolai Podoltsev, MD, PhD, discusses approaches for mitigating and managing TKI- ... more >>
  • Leukemia — Selection of a Tyrosine Kinase Inhibitor for Relapsed, Resistant, and Intolerant CML: Comparing Benefits and Risks – Webcast
  • This activity focuses on an overview of the clinical data supporting the use of tyrosine kinase inhibitors (TKIs) for the treatment of relapsed, resistant, and intolerant chronic myeloid leukemia. Jorge Cortes, MD, presents key efficacy and safety data for the different TKIs and discusses strategies to select ... more >>
    J. Cortes,
  • Leukemia — Beyond First-Line Therapy: Consideration for Individualizing TKI Selection – Webcast
  • In this brief presentation, Nikolai Podoltsev, MD, PhD, highlights key considerations for individualizing later-line therapy for patients with chronic myeloid leukemia. Using a case study, Dr. Podoltsev explains how to determine whether a change in treatment is warranted, and he summarizes the disease and ... more >>
  • Leukemia — Patient Monitoring and When to Modify Therapy for Resistance – Webcast
  • This activity highlights strategies for developing a treatment plan for an individual diagnosed with chronic myeloid leukemia (CML). Most importantly, Michael J Mauro, MD, reviews key milestones of response to tyrosine kinase inhibitors and the importance of early molecular response in terms of long-term ... more >>
    M. Mauro, MD
  • Leukemia — Noncardiovascular Adverse Events Associated With Tyrosine Kinase Inhibitors Used for CML and Their Management – Webcast
  • Adverse events are common in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, and they have the potential to impact life quality, drug adherence, and disease response. Julie Baker, DNP, MS, APRN, guides viewers through the unique toxicity profile of each tyrosine kinase ... more >>
  • Leukemia — Cardiotoxicities of TKIs – Webcast
  • Elias Jabbour, MD, provides a punchy review of the data illustrating the differences among the tyrosine kinase inhibitors in cardiovascular adverse events, the magnitude of the risk, and changes in risk over time. After summarizing the risk:benefit trade-off, Dr. Jabbour reviews best practices for ... more >>
    E. Jabbour, MD
  • Leukemia — Case Study: Initiation of First-Line Treatment in Patient With Symptomatic CLL and del(17p)/TP53 Mutation – Case Study
  • In this master class, Dr. William Wierda discusses a 64-year-old male patient with untreated chronic lymphocytic leukemia who developed leukocytosis, became symptomatic, and needed treatment. The case considers the initial evaluation and diagnosis of this patient, including his immunologic and genetic profile ... more >>
    W. Wierda, MD, PhD
  • Leukemia — Case Study: Achieving Durable Response After Progression on Ibrutinib – Case Study
  • Ibrutinib has improved survival for patients with relapsed, high-risk chronic lymphocytic leukemia, but patients who relapse after ibrutinib pose a challenging clinical scenario. This case study reviews the efficacy and safety data on treatment options to achieve a durable response in a 74-year-old man who ... more >>
    A. Mato, MD, MSCE
    L. Roeker, MD, MSCE
  • Leukemia — Case Study: Optimizing CLL Management: Venetoclax Dosing and TLS Prophylaxis – Case Study
  • Small-molecule inhibitors have improved outcomes for patients with del(17p)-positive chronic lymphocytic leukemia (CLL), a population with a historically poor prognosis, yet they do pose potentially serious risks. This case study reviews the efficacy and safety data of treatment options for a 78-year-old man ... more >>
    B. Cheson, MD, FACP, FAAAS
    M. Yazdy, MD
  • Multiple Myeloma — High-Risk Relapsing MM: Retreatment With Immunomodulatory Therapy – Case Study
  • Determination of the best treatment for a high-risk multiple myeloma patient is based on a complex set of factors, including risk evaluation, patient comorbidities, patient desires, and the need to achieve a satisfactory response as quickly as possible. In this case, Dr. Lentzsch discusses the problems ... more >>
    S. Lentzsch, MD, PhD
  • Multiple Myeloma — Relapsing/Refractory Multiple Myeloma in a High Risk Patient: Efficacy With Monoclonal Antibody Therapy as Part of Triple Therapy – Case Study
  • Choosing the appropriate therapy for transplant-deferred patients with relapsed multiple myeloma (MM) can be challenging; there are now emerging combination treatments available, each with their own efficacy and safety profiles. This case illustrates the real-life case scenario of a patient with relapsed MM ... more >>
    N. Raje, MD
  • Multiple Myeloma — Treatment of a Relapsing High-Risk Multiple Myeloma Patient – Case Study
  • Today there are many options for the treatment of patients with relapsed multiple myeloma, as well as more treatments in development. This case illustrates the real-life scenario of a patient with relapsed multiple myeloma with evolution of his disease at the time of relapse introducing a high-risk ... more >>
    S. Kumar, MD
  • Multiple Myeloma — Treatment of a Patient with Relapsed/Refractory Multiple Myeloma and No Comorbidities – Case Study
  • Today there are multiple options for the treatment of patients with relapsed or refractory multiple myeloma, as well as further treatments in development. This case illustrates the real-life scenario of a patient with relapsed, bortezomib-refractory multiple myeloma, and discusses the treatment options ... more >>
    S. Bringhen, MD, PhD
  • Multiple Myeloma — Role of Proteasome Inhibitor Therapy in a Patient with High-Risk Relapsing Multiple Myeloma – Case Study
  • High-risk multiple myeloma is challenging to manage, as these patients tend to have aggressive disease, transient responses to treatment, and short overall survival. This case illustrates the real-life scenario of a patient with high-risk multiple myeloma and disease progression after initial treatment with ... more >>
    J. Shah, MD
  • Multiple Myeloma — Case Study: Role of Immunomodulatory Drug Therapy in a Patient with Refractory Multiple Myeloma – Case Study
  • Today there have been many scientific advances resulting in newly approved treatment options, as well as many more in development, that offer patients with relapsing or refractory multiple myeloma (MM) opportunities to prolong progression-free and overall survival. This case illustrates the real-life scenario ... more >>
    K. Anderson, MD
  • Multiple Myeloma — High-Risk Relapsing MM Patient: Efficacy of a Proteasome Inhibitor – Case Study
  • Patients who are at high risk for progression and are in good clinical condition should be considered for induction therapy with a novel agent and autologous stem cell transplantation . In this case, Dr. Bringhen discusses induction therapy and presents evidence to support the use of proteasome inhibitor ... more >>
    S. Bringhen, MD, PhD

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information